← Back to all substances
A

liraglutide

139ms
Level 1

✓ What this shows

  • • Reported adverse events from FDA FAERS
  • • Descriptive statistics from a locked corpus
  • • Data verified with cryptographic hashes

✗ What this is NOT

  • • Not medical advice or recommendations
  • • Not proof of causality
  • • Not a complete safety profile

About this substance

Class: GLP-1 Receptor Agonist [EPC]

1 INDICATIONS AND USAGE Liraglutide injection is indicated: as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus Limitations of Use: Liraglutide injection contains liraglutide. Coadministration with othe...

Known as: Liraglutide
Route: SUBCUTANEOUS
Source: OpenFDA Drug Labels · Reference only · Not medical advice
500
Events in Corpus
v20260131-01
4,993
Total in FDA
86%
Serious Reports
48
Fatal Outcomes

Seriousness

Serious
431
Non-Serious
69

Sex Distribution

Male
233
Female
233
Unknown
34

Age Distribution

0-17
3
18-40
25
41-64
232
65-84
161
85+
4
Unknown
75

Outcomes

Recovered/Resolved
412
Recovering/Resolving
110
Not Recovered/Not Resolved
195
Recovered with Sequelae
32
Fatal
48
Unknown
458

Top Reported Reactions (click to view reports)

Verification Data

Corpus Version: v20260131-01
Root Hash: ec5727564d1ed19be5b08b26d3866f446b12d3d388f5a8cd713332c6d97ad264
Stats Hash: N/A
EVE Decision ID: EVE-MED-20260402-327e1c
ℹThis output reports adverse events from FDA FAERS. It does not constitute medical advice.

Molecular Structure (reference)

Structural visualization for identification only.

This visualization shows the molecular structure for identification purposes only. It does not represent pharmacological effect, safety, or clinical relevance.

Loading structure...